Advertisement

Topics

San Diego’s Amplyx Raises $67M to Advance New Anti-Fungal Drug

02:01 EDT 2 Aug 2017 | Xconomy

After completing an early stage evaluation of its broad-spectrum anti-fungal drug, San Diego’s Amplyx Pharmaceuticals said Wednesday it has raised $67 million in a Series C financing round led by a new investor, Sofinnova Venture Partners. Ciara Kennedy, who succeeded Mike Grey as Amplyx CEO late last year, said in an interview with Xconomy that […]

Original Article: San Diego’s Amplyx Raises $67M to Advance New Anti-Fungal Drug

NEXT ARTICLE

More From BioPortfolio on "San Diego’s Amplyx Raises $67M to Advance New Anti-Fungal Drug"

Quick Search
Advertisement
 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...